151 related articles for article (PubMed ID: 23621218)
1. Evidence for enhanced telomerase activity in Barrett's esophagus with dysplasia and adenocarcinoma.
Merchant NB; Dutta SK; Girotra M; Arora M; Meltzer SJ
Asian Pac J Cancer Prev; 2013; 14(2):679-83. PubMed ID: 23621218
[TBL] [Abstract][Full Text] [Related]
2. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
3. Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus.
Going JJ; Fletcher-Monaghan AJ; Neilson L; Wisman BA; van der Zee A; Stuart RC; Keith WN
Neoplasia; 2004; 6(1):85-92. PubMed ID: 15068673
[TBL] [Abstract][Full Text] [Related]
4. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Morales CP; Lee EL; Shay JW
Cancer; 1998 Aug; 83(4):652-9. PubMed ID: 9708927
[TBL] [Abstract][Full Text] [Related]
5. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
7. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.
Huhta H; Helminen O; Lehenkari PP; Saarnio J; Karttunen TJ; Kauppila JH
Oncotarget; 2016 Apr; 7(17):23658-67. PubMed ID: 27008696
[TBL] [Abstract][Full Text] [Related]
9. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
10. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
[TBL] [Abstract][Full Text] [Related]
11. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia.
Lu D; Vohra P; Chu PG; Woda B; Rock KL; Jiang Z
Am J Surg Pathol; 2009 Apr; 33(4):521-5. PubMed ID: 19047899
[TBL] [Abstract][Full Text] [Related]
12. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
13. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
14. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
15. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
[TBL] [Abstract][Full Text] [Related]
16. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
17. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
18. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
19. Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study.
Sharma P; Marcon N; Wani S; Bansal A; Mathur S; Sampliner R; Lightdale C
Endoscopy; 2006 Dec; 38(12):1206-12. PubMed ID: 17163320
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]